T Cell‐Mediated Transport of Polymer Nanoparticles across the Blood–Brain Barrier
Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood–brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively...
Saved in:
Published in | Advanced healthcare materials Vol. 10; no. 2; pp. e2001375 - n/a |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Wiley Subscription Services, Inc
01.01.2021
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood–brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively unexplored, yet very attractive. This paper presents a first proof‐of‐concept that demonstrates the feasibility of activated effector/memory CD4+ helper T cells (CD4+ TEM cells) as carriers for the delivery of polymer nanoparticles across the BBB. This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)‐modified polystyrene nanoparticles using thiol–maleimide coupling chemistry, resulting in the immobilization of ≈105 nanoparticles per cell as determined by confocal microscopy. The ability of these cells to serve as carriers to transport nanoparticles across the BBB is established in vitro and in vivo. Using in vitro BBB models, CD4+ TEM cells are found to be able to transport nanoparticles across the BBB both under static conditions as well as under physiological flow. Finally, upon systemic administration, nanoparticle‐modified T cells are shown to enter the brain parenchyma of mice, demonstrating the brain delivery potential of this T cell subset in allogeneic hosts.
CD4+ helper T cells can be surface‐modified via thiol–maleimide chemistry with polymer nanoparticles. These modified cells can act as carriers that allow for the transport of the nanoparticle cargo across the blood–brain barrier both in vitro as well as in vivo. |
---|---|
AbstractList | Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood-brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively unexplored, yet very attractive. This paper presents a first proof-of-concept that demonstrates the feasibility of activated effector/memory CD4+ helper T cells (CD4+ TEM cells) as carriers for the delivery of polymer nanoparticles across the BBB. This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)-modified polystyrene nanoparticles using thiol-maleimide coupling chemistry, resulting in the immobilization of ≈105 nanoparticles per cell as determined by confocal microscopy. The ability of these cells to serve as carriers to transport nanoparticles across the BBB is established in vitro and in vivo. Using in vitro BBB models, CD4+ TEM cells are found to be able to transport nanoparticles across the BBB both under static conditions as well as under physiological flow. Finally, upon systemic administration, nanoparticle-modified T cells are shown to enter the brain parenchyma of mice, demonstrating the brain delivery potential of this T cell subset in allogeneic hosts.Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood-brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively unexplored, yet very attractive. This paper presents a first proof-of-concept that demonstrates the feasibility of activated effector/memory CD4+ helper T cells (CD4+ TEM cells) as carriers for the delivery of polymer nanoparticles across the BBB. This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)-modified polystyrene nanoparticles using thiol-maleimide coupling chemistry, resulting in the immobilization of ≈105 nanoparticles per cell as determined by confocal microscopy. The ability of these cells to serve as carriers to transport nanoparticles across the BBB is established in vitro and in vivo. Using in vitro BBB models, CD4+ TEM cells are found to be able to transport nanoparticles across the BBB both under static conditions as well as under physiological flow. Finally, upon systemic administration, nanoparticle-modified T cells are shown to enter the brain parenchyma of mice, demonstrating the brain delivery potential of this T cell subset in allogeneic hosts. Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood–brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively unexplored, yet very attractive. This paper presents a first proof‐of‐concept that demonstrates the feasibility of activated effector/memory CD4 + helper T cells (CD4 + T EM cells) as carriers for the delivery of polymer nanoparticles across the BBB. This study shows that CD4 + T EM cells can be decorated with poly(ethylene glycol)‐modified polystyrene nanoparticles using thiol–maleimide coupling chemistry, resulting in the immobilization of ≈105 nanoparticles per cell as determined by confocal microscopy. The ability of these cells to serve as carriers to transport nanoparticles across the BBB is established in vitro and in vivo. Using in vitro BBB models, CD4 + T EM cells are found to be able to transport nanoparticles across the BBB both under static conditions as well as under physiological flow. Finally, upon systemic administration, nanoparticle‐modified T cells are shown to enter the brain parenchyma of mice, demonstrating the brain delivery potential of this T cell subset in allogeneic hosts. CD4 + helper T cells can be surface‐modified via thiol–maleimide chemistry with polymer nanoparticles. These modified cells can act as carriers that allow for the transport of the nanoparticle cargo across the blood–brain barrier both in vitro as well as in vivo. Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood–brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively unexplored, yet very attractive. This paper presents a first proof‐of‐concept that demonstrates the feasibility of activated effector/memory CD4+ helper T cells (CD4+ TEM cells) as carriers for the delivery of polymer nanoparticles across the BBB. This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)‐modified polystyrene nanoparticles using thiol–maleimide coupling chemistry, resulting in the immobilization of ≈105 nanoparticles per cell as determined by confocal microscopy. The ability of these cells to serve as carriers to transport nanoparticles across the BBB is established in vitro and in vivo. Using in vitro BBB models, CD4+ TEM cells are found to be able to transport nanoparticles across the BBB both under static conditions as well as under physiological flow. Finally, upon systemic administration, nanoparticle‐modified T cells are shown to enter the brain parenchyma of mice, demonstrating the brain delivery potential of this T cell subset in allogeneic hosts. CD4+ helper T cells can be surface‐modified via thiol–maleimide chemistry with polymer nanoparticles. These modified cells can act as carriers that allow for the transport of the nanoparticle cargo across the blood–brain barrier both in vitro as well as in vivo. Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood-brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively unexplored, yet very attractive. This paper presents a first proof-of-concept that demonstrates the feasibility of activated effector/memory CD4 helper T cells (CD4 T cells) as carriers for the delivery of polymer nanoparticles across the BBB. This study shows that CD4 T cells can be decorated with poly(ethylene glycol)-modified polystyrene nanoparticles using thiol-maleimide coupling chemistry, resulting in the immobilization of ≈105 nanoparticles per cell as determined by confocal microscopy. The ability of these cells to serve as carriers to transport nanoparticles across the BBB is established in vitro and in vivo. Using in vitro BBB models, CD4 T cells are found to be able to transport nanoparticles across the BBB both under static conditions as well as under physiological flow. Finally, upon systemic administration, nanoparticle-modified T cells are shown to enter the brain parenchyma of mice, demonstrating the brain delivery potential of this T cell subset in allogeneic hosts. Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood–brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively unexplored, yet very attractive. This paper presents a first proof‐of‐concept that demonstrates the feasibility of activated effector/memory CD4 + helper T cells (CD4 + T EM cells) as carriers for the delivery of polymer nanoparticles across the BBB. This study shows that CD4 + T EM cells can be decorated with poly(ethylene glycol)‐modified polystyrene nanoparticles using thiol–maleimide coupling chemistry, resulting in the immobilization of ≈105 nanoparticles per cell as determined by confocal microscopy. The ability of these cells to serve as carriers to transport nanoparticles across the BBB is established in vitro and in vivo. Using in vitro BBB models, CD4 + T EM cells are found to be able to transport nanoparticles across the BBB both under static conditions as well as under physiological flow. Finally, upon systemic administration, nanoparticle‐modified T cells are shown to enter the brain parenchyma of mice, demonstrating the brain delivery potential of this T cell subset in allogeneic hosts. Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood–brain barrier (BBB). Amongst various approaches that have been explored to facilitate drug delivery to the CNS, the use of cells that have the intrinsic ability to cross the BBB is relatively unexplored, yet very attractive. This paper presents a first proof‐of‐concept that demonstrates the feasibility of activated effector/memory CD4+ helper T cells (CD4+ TEM cells) as carriers for the delivery of polymer nanoparticles across the BBB. This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)‐modified polystyrene nanoparticles using thiol–maleimide coupling chemistry, resulting in the immobilization of ≈105 nanoparticles per cell as determined by confocal microscopy. The ability of these cells to serve as carriers to transport nanoparticles across the BBB is established in vitro and in vivo. Using in vitro BBB models, CD4+ TEM cells are found to be able to transport nanoparticles across the BBB both under static conditions as well as under physiological flow. Finally, upon systemic administration, nanoparticle‐modified T cells are shown to enter the brain parenchyma of mice, demonstrating the brain delivery potential of this T cell subset in allogeneic hosts. |
Author | Seitz, Arne Kaba, Elisa Ayer, Maxime Gruber, Isabelle Blatti, Claudia Burri, Olivier Schuster, Markus Enzmann, Gaby Engelhardt, Britta Guiet, Romain Klok, Harm‐Anton |
AuthorAffiliation | 1 École Polytechnique Fédérale de Lausanne (EPFL) Institut des Matériaux and Institut des Sciences et Ingénierie Chimiques Laboratoire des Polymères Bâtiment MXD Station 12 Lausanne CH‐1015 Switzerland 2 Theodor Kocher Institute University of Bern Freiestrasse 1 Bern CH‐3012 Switzerland 3 École Polytechnique Fédérale de Lausanne (EPFL) Faculté des sciences de la vie Bioimaging and Optics Platform Bâtiment AI, Station 15 Lausanne CH‐1015 Switzerland |
AuthorAffiliation_xml | – name: 2 Theodor Kocher Institute University of Bern Freiestrasse 1 Bern CH‐3012 Switzerland – name: 3 École Polytechnique Fédérale de Lausanne (EPFL) Faculté des sciences de la vie Bioimaging and Optics Platform Bâtiment AI, Station 15 Lausanne CH‐1015 Switzerland – name: 1 École Polytechnique Fédérale de Lausanne (EPFL) Institut des Matériaux and Institut des Sciences et Ingénierie Chimiques Laboratoire des Polymères Bâtiment MXD Station 12 Lausanne CH‐1015 Switzerland |
Author_xml | – sequence: 1 givenname: Maxime surname: Ayer fullname: Ayer, Maxime organization: Bâtiment MXD – sequence: 2 givenname: Markus surname: Schuster fullname: Schuster, Markus organization: Bâtiment MXD – sequence: 3 givenname: Isabelle surname: Gruber fullname: Gruber, Isabelle organization: University of Bern – sequence: 4 givenname: Claudia surname: Blatti fullname: Blatti, Claudia organization: University of Bern – sequence: 5 givenname: Elisa surname: Kaba fullname: Kaba, Elisa organization: University of Bern – sequence: 6 givenname: Gaby surname: Enzmann fullname: Enzmann, Gaby organization: University of Bern – sequence: 7 givenname: Olivier surname: Burri fullname: Burri, Olivier organization: Bioimaging and Optics Platform – sequence: 8 givenname: Romain surname: Guiet fullname: Guiet, Romain organization: Bioimaging and Optics Platform – sequence: 9 givenname: Arne surname: Seitz fullname: Seitz, Arne organization: Bioimaging and Optics Platform – sequence: 10 givenname: Britta surname: Engelhardt fullname: Engelhardt, Britta email: bengel@tki.unibe.ch organization: University of Bern – sequence: 11 givenname: Harm‐Anton orcidid: 0000-0003-3365-6543 surname: Klok fullname: Klok, Harm‐Anton email: harm-anton.klok@epfl.ch organization: Bâtiment MXD |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33241667$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1uEzEUhS1UREvpliWyxKabBNvj8YxXqAnQIrXAIl1bNx6buPLYwZ6AsusjIPGGfZI6pE2hEsJe2NL9zv059znaCzEYhF5SMqaEsDfQLfoxI4wQWjX1E3TAqGQjJmq5t_tzso-Ocr4i5YiaipY-Q_tVxTgVojlAlzM8Nd7fXP-8MJ2DwXR4liDkZUwDjhZ_iX7dm4Q_QYhLSIPT3mQMOsWc8bAweOJj7G6uf00SuIAnkJIz6QV6asFnc3T3HqLLD-9n07PR-efTj9OT85HmQtajTs7nVgBveQ111VnLpa06o1sNDISBpraN5vWcS6opAWK4aEHYzrISqQRUh-jtNu9yNe9Np00YEni1TK6HtFYRnPo7EtxCfY3fFaWlgeJByXB8lyHFbyuTB9W7rIsjEExcZcW44IKUKwv6-hF6FVcplPkK1bSSU1K1hXr1Z0u7Xu4tL8B4C_z2MBm7QyhRm7WqzVrVbq1FwB8JtBtgcHEzkvP_lsmt7IfzZv2fIurk3dnFg_YWq7y5jA |
CitedBy_id | crossref_primary_10_1021_acsabm_0c01619 crossref_primary_10_1021_acs_biomac_1c00488 crossref_primary_10_1039_D1CS00574J crossref_primary_10_1002_adhm_202100812 crossref_primary_10_1016_j_bbi_2023_11_004 crossref_primary_10_1002_adma_202304963 crossref_primary_10_1016_j_bbcan_2022_188703 crossref_primary_10_1016_j_addr_2021_113832 crossref_primary_10_1016_j_ejpb_2024_114446 crossref_primary_10_1016_j_lfs_2021_120108 crossref_primary_10_1021_acs_molpharmaceut_3c01167 crossref_primary_10_1039_D4NR02636E crossref_primary_10_1021_acs_bioconjchem_1c00026 crossref_primary_10_1039_D3NR04241C crossref_primary_10_1039_D1TB02015C crossref_primary_10_1186_s12951_021_01002_3 crossref_primary_10_1016_j_jconrel_2022_09_065 crossref_primary_10_1002_adfm_202409522 crossref_primary_10_1021_acsnano_3c10674 crossref_primary_10_1016_j_colsurfb_2022_112999 crossref_primary_10_1016_j_colsurfb_2025_114499 crossref_primary_10_1002_adfm_202206346 crossref_primary_10_1021_acsnano_2c02850 crossref_primary_10_2147_IJN_S457393 crossref_primary_10_1016_j_jconrel_2024_05_044 crossref_primary_10_3390_pharmaceutics16121611 crossref_primary_10_3389_fbioe_2022_984424 crossref_primary_10_1016_j_jddst_2023_105050 crossref_primary_10_1038_s41551_024_01230_6 crossref_primary_10_1007_s11064_025_04333_x crossref_primary_10_1021_acsnano_3c11464 crossref_primary_10_3390_pharmaceutics13070948 crossref_primary_10_1002_wnan_1853 crossref_primary_10_1016_j_addr_2022_114415 crossref_primary_10_1016_j_cclet_2022_05_032 crossref_primary_10_1002_adbi_202101293 crossref_primary_10_1002_adfm_202214842 crossref_primary_10_1080_1061186X_2022_2104299 crossref_primary_10_1126_scitranslmed_adh1150 crossref_primary_10_1080_08982104_2023_2270060 crossref_primary_10_1186_s12951_022_01479_6 crossref_primary_10_1021_acs_molpharmaceut_4c00447 crossref_primary_10_3897_pharmacia_70_e98838 crossref_primary_10_3390_pharmaceutics15041257 crossref_primary_10_1021_acs_chemrev_3c00062 |
Cites_doi | 10.1517/17425247.2011.559457 10.1097/00004647-200109000-00009 10.1016/j.jconrel.2016.05.044 10.1038/ni.3423 10.1016/j.jconrel.2017.01.048 10.1038/nature08478 10.4049/jimmunol.0903732 10.1021/bc700184b 10.1038/ni.3666 10.1073/pnas.97.23.12846 10.1016/j.jconrel.2014.03.050 10.1016/j.it.2012.07.004 10.1021/ab500179h 10.2217/nnm.10.7 10.2217/fon.13.217 10.1038/nrm2680 10.1007/s11095-010-0291-7 10.2217/nnm.11.32 10.1016/j.nbd.2009.07.030 10.1016/j.brainres.2009.08.076 10.1016/j.jconrel.2012.04.044 10.1111/j.1600-065X.2012.01140.x 10.1016/j.biomaterials.2012.04.029 10.1186/2045-8118-10-7 10.2217/nnm.11.156 10.1172/JCI12440 10.1038/nm.2198 10.1038/nnano.2017.54 10.1038/jcbfm.2010.96 10.1016/S1773-2247(13)50061-X 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.0.CO;2-Z 10.1038/nature16939 10.1038/jcbfm.2012.126 |
ContentType | Journal Article |
Copyright | 2020 The Authors. Published by Wiley‐VCH GmbH 2020 The Authors. Published by Wiley-VCH GmbH. 2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2020 The Authors. Published by Wiley‐VCH GmbH – notice: 2020 The Authors. Published by Wiley-VCH GmbH. – notice: 2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QF 7QP 7QQ 7SC 7SE 7SP 7SR 7T5 7TA 7TB 7TM 7TO 7U5 8BQ 8FD F28 FR3 H8D H8G H94 JG9 JQ2 K9. KR7 L7M L~C L~D 7X8 5PM |
DOI | 10.1002/adhm.202001375 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Aluminium Industry Abstracts Calcium & Calcified Tissue Abstracts Ceramic Abstracts Computer and Information Systems Abstracts Corrosion Abstracts Electronics & Communications Abstracts Engineered Materials Abstracts Immunology Abstracts Materials Business File Mechanical & Transportation Engineering Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Solid State and Superconductivity Abstracts METADEX Technology Research Database ANTE: Abstracts in New Technology & Engineering Engineering Research Database Aerospace Database Copper Technical Reference Library AIDS and Cancer Research Abstracts Materials Research Database ProQuest Computer Science Collection ProQuest Health & Medical Complete (Alumni) Civil Engineering Abstracts Advanced Technologies Database with Aerospace Computer and Information Systems Abstracts Academic Computer and Information Systems Abstracts Professional MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Materials Research Database Oncogenes and Growth Factors Abstracts Technology Research Database Computer and Information Systems Abstracts – Academic Mechanical & Transportation Engineering Abstracts Nucleic Acids Abstracts ProQuest Computer Science Collection Computer and Information Systems Abstracts ProQuest Health & Medical Complete (Alumni) Materials Business File Aerospace Database Copper Technical Reference Library Engineered Materials Abstracts AIDS and Cancer Research Abstracts Advanced Technologies Database with Aerospace ANTE: Abstracts in New Technology & Engineering Civil Engineering Abstracts Aluminium Industry Abstracts Electronics & Communications Abstracts Ceramic Abstracts METADEX Computer and Information Systems Abstracts Professional Immunology Abstracts Solid State and Superconductivity Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Corrosion Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Materials Research Database |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access (WRLC) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 2192-2659 |
EndPage | n/a |
ExternalDocumentID | PMC11469241 33241667 10_1002_adhm_202001375 ADHM202001375 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Swiss National Science Foundation – fundername: Horizon 2020 Framework Programme – fundername: Flow Cytometry Core Facility – fundername: European Union Horizon 2020 funderid: MSCA‐ITN‐215 675619 – fundername: European Union Horizon 2020 grantid: MSCA‐ITN‐215 675619 |
GroupedDBID | 05W 0R~ 1OC 24P 33P 53G 8-0 8-1 A00 AAESR AAHHS AAHQN AAIHA AAIPD AAMNL AANLZ AAXRX AAYCA AAZKR ABCUV ABLJU ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACIWK ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AENEX AEQDE AEUYR AFBPY AFFPM AFGKR AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB AZVAB BDRZF BFHJK BMXJE BRXPI D-A D-B DCZOG DRFUL DRMAN DRSTM EBD EBS EMOBN G-S HGLYW HZ~ KBYEO LATKE LEEKS LITHE LOXES LUTES LYRES MEWTI MXFUL MXMAN MXSTM MY. MY~ O9- P2W PQQKQ ROL SUPJJ SV3 WBKPD WOHZO WXSBR WYJ ZZTAW 31~ AANHP AASGY AAYXX ACBWZ ACRPL ACYXJ ADMLS ADNMO AEYWJ AGHNM AGQPQ AGYGG ASPBG AVWKF AZFZN C45 CITATION EJD GODZA OVD TEORI CGR CUY CVF ECM EIF NPM 7QF 7QP 7QQ 7SC 7SE 7SP 7SR 7T5 7TA 7TB 7TM 7TO 7U5 8BQ 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY F28 FR3 H8D H8G H94 JG9 JQ2 K9. KR7 L7M L~C L~D 7X8 5PM |
ID | FETCH-LOGICAL-c4695-d9bbf6a4845a53dff49f3dec8ca2a6ea75f7c45b491c10a0e468a6fdf275f36a3 |
IEDL.DBID | 24P |
ISSN | 2192-2640 2192-2659 |
IngestDate | Thu Aug 21 18:34:59 EDT 2025 Fri Jul 11 10:51:11 EDT 2025 Fri Jul 25 12:02:24 EDT 2025 Thu Apr 03 06:54:05 EDT 2025 Tue Jul 01 03:06:40 EDT 2025 Thu Apr 24 23:10:32 EDT 2025 Wed Jan 22 16:30:15 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | blood-brain barriers nanoparticles cell-surface modifications nanomedicines cell-mediated deliveries |
Language | English |
License | Attribution 2020 The Authors. Published by Wiley-VCH GmbH. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4695-d9bbf6a4845a53dff49f3dec8ca2a6ea75f7c45b491c10a0e468a6fdf275f36a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-3365-6543 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadhm.202001375 |
PMID | 33241667 |
PQID | 2478941038 |
PQPubID | 2032434 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11469241 proquest_miscellaneous_2464606069 proquest_journals_2478941038 pubmed_primary_33241667 crossref_primary_10_1002_adhm_202001375 crossref_citationtrail_10_1002_adhm_202001375 wiley_primary_10_1002_adhm_202001375_ADHM202001375 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-01-01 |
PublicationDateYYYYMMDD | 2021-01-01 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Weinheim – name: Hoboken |
PublicationTitle | Advanced healthcare materials |
PublicationTitleAlternate | Adv Healthc Mater |
PublicationYear | 2021 |
Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
References | 2015; 1 2007; 18 2012; 164 1998; 28 2010; 16 2010; 37 2013; 23 2014; 190 2011; 31 2010; 185 2001; 108 2016; 17 2011; 6 2012; 248 2012; 33 2012; 32 2011; 8 2017; 259 2001; 21 2009; 10 2013; 10 2017; 12 2000; 97 2009; 462 2016; 530 2011; S4 2017; 18 2016; 235 2011; 28 2012; 7 2010; 5 2009; 1298 2014; 10 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_1_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 Zhao Y. (e_1_2_8_13_1) 2011; 4 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
References_xml | – volume: 10 start-page: 7 year: 2013 publication-title: Fluids Barriers CNS – volume: 18 start-page: 123 year: 2017 publication-title: Nat. Immunol. – volume: 259 start-page: 92 year: 2017 publication-title: J. Controlled Release – volume: 6 start-page: 1215 year: 2011 publication-title: Nanomedicine – volume: 10 start-page: 401 year: 2014 publication-title: Future Oncol. – volume: 31 start-page: 315 year: 2011 publication-title: J. Cereb. Blood Flow Metab. – volume: 37 start-page: 13 year: 2010 publication-title: Neurobiol. Dis. – volume: 28 start-page: 456 year: 2011 publication-title: Pharm. Res. – volume: 18 start-page: 1498 year: 2007 publication-title: Bioconjug. Chem. – volume: 7 start-page: 815 year: 2012 publication-title: Nanomedicine – volume: 10 start-page: 353 year: 2009 publication-title: Nat. Rev. Mol. Cell Biol. – volume: 235 start-page: 34 year: 2016 publication-title: J. Controlled Release – volume: 33 start-page: 579 year: 2012 publication-title: Trends Immunol. – volume: 5 start-page: 379 year: 2010 publication-title: Nanomedicine – volume: 190 start-page: 531 year: 2014 publication-title: J. Controlled Release – volume: 164 start-page: 145 year: 2012 publication-title: J. Controlled Release – volume: 97 year: 2000 publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 185 start-page: 4846 year: 2010 publication-title: J. Immunol. – volume: S4 start-page: 003 year: 2011 publication-title: J. Nanomed. Nanotechnol. – volume: 33 start-page: 5776 year: 2012 publication-title: Biomaterials – volume: 530 start-page: 349 year: 2016 publication-title: Nature – volume: 23 start-page: 419 year: 2013 publication-title: J. Drug Deliv. Sci. Technol. – volume: 1298 start-page: 13 year: 2009 publication-title: Brain Res. – volume: 16 start-page: 1035 year: 2010 publication-title: Nat. Med. – volume: 1 start-page: 201 year: 2015 publication-title: ACS Biomater. Sci. Eng. – volume: 462 start-page: 94 year: 2009 publication-title: Nature – volume: 28 start-page: 3086 year: 1998 publication-title: Eur. J. Immunol. – volume: 32 start-page: 1959 year: 2012 publication-title: J. Cereb. Blood Flow Metab. – volume: 21 start-page: 1115 year: 2001 publication-title: J. Cereb. Blood Flow Metab. – volume: 248 start-page: 216 year: 2012 publication-title: Immunol. Rev. – volume: 108 start-page: 557 year: 2001 publication-title: J. Clin. Invest. – volume: 8 start-page: 415 year: 2011 publication-title: Expert Opin. Drug Deliv. – volume: 17 start-page: 797 year: 2016 publication-title: Nat. Immunol. – volume: 12 start-page: 692 year: 2017 publication-title: Nat. Nanotechnol. – ident: e_1_2_8_9_1 doi: 10.1517/17425247.2011.559457 – ident: e_1_2_8_18_1 doi: 10.1097/00004647-200109000-00009 – ident: e_1_2_8_4_1 doi: 10.1016/j.jconrel.2016.05.044 – ident: e_1_2_8_16_1 doi: 10.1038/ni.3423 – ident: e_1_2_8_8_1 doi: 10.1016/j.jconrel.2017.01.048 – ident: e_1_2_8_26_1 doi: 10.1038/nature08478 – ident: e_1_2_8_25_1 doi: 10.4049/jimmunol.0903732 – ident: e_1_2_8_11_1 doi: 10.1021/bc700184b – ident: e_1_2_8_27_1 doi: 10.1038/ni.3666 – ident: e_1_2_8_21_1 doi: 10.1073/pnas.97.23.12846 – ident: e_1_2_8_6_1 doi: 10.1016/j.jconrel.2014.03.050 – ident: e_1_2_8_24_1 doi: 10.1016/j.it.2012.07.004 – ident: e_1_2_8_7_1 doi: 10.1021/ab500179h – ident: e_1_2_8_12_1 doi: 10.2217/nnm.10.7 – volume: 4 start-page: 003 year: 2011 ident: e_1_2_8_13_1 publication-title: J. Nanomed. Nanotechnol. – ident: e_1_2_8_20_1 doi: 10.2217/fon.13.217 – ident: e_1_2_8_33_1 doi: 10.1038/nrm2680 – ident: e_1_2_8_5_1 doi: 10.1007/s11095-010-0291-7 – ident: e_1_2_8_15_1 doi: 10.2217/nnm.11.32 – ident: e_1_2_8_1_1 doi: 10.1016/j.nbd.2009.07.030 – ident: e_1_2_8_19_1 doi: 10.1016/j.brainres.2009.08.076 – ident: e_1_2_8_2_1 doi: 10.1016/j.jconrel.2012.04.044 – ident: e_1_2_8_23_1 doi: 10.1111/j.1600-065X.2012.01140.x – ident: e_1_2_8_32_1 doi: 10.1016/j.biomaterials.2012.04.029 – ident: e_1_2_8_34_1 doi: 10.1186/2045-8118-10-7 – ident: e_1_2_8_14_1 doi: 10.2217/nnm.11.156 – ident: e_1_2_8_22_1 doi: 10.1172/JCI12440 – ident: e_1_2_8_29_1 doi: 10.1038/nm.2198 – ident: e_1_2_8_17_1 doi: 10.1038/nnano.2017.54 – ident: e_1_2_8_31_1 doi: 10.1038/jcbfm.2010.96 – ident: e_1_2_8_10_1 doi: 10.1016/S1773-2247(13)50061-X – ident: e_1_2_8_30_1 doi: 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.0.CO;2-Z – ident: e_1_2_8_28_1 doi: 10.1038/nature16939 – ident: e_1_2_8_3_1 doi: 10.1038/jcbfm.2012.126 |
SSID | ssj0000651681 |
Score | 2.4434254 |
Snippet | Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood–brain barrier (BBB). Amongst various approaches... Delivery of therapeutics to the central nervous system (CNS) is challenging due to the presence of the blood-brain barrier (BBB). Amongst various approaches... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e2001375 |
SubjectTerms | Animals Biological Transport Blood-Brain Barrier blood–brain barriers CD4 antigen Cell culture cell‐mediated deliveries cell‐surface modifications Central nervous system Confocal microscopy Drug delivery Drug Delivery Systems Immobilization Immunological memory Lymphocytes Lymphocytes T Memory cells Mice nanomedicines Nanoparticles Parenchyma Polyethylene glycol Polymers Polystyrene Polystyrene resins T-Lymphocytes |
Title | T Cell‐Mediated Transport of Polymer Nanoparticles across the Blood–Brain Barrier |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadhm.202001375 https://www.ncbi.nlm.nih.gov/pubmed/33241667 https://www.proquest.com/docview/2478941038 https://www.proquest.com/docview/2464606069 https://pubmed.ncbi.nlm.nih.gov/PMC11469241 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEB7a5NIeSv_rNgkqFHoysWVJto67-WEp3RJoFnIzY1kihY23bJJDb3mEQt4wTxKN7FV3CaXQo9HYFpoZzYw08w3AJ2yUKaRqUpd5CfYWw6TeDMs0R61QVw6doXrn6Tc1mYkvZ_JsrYq_x4eIB26kGWG_JgXH5nL_D2gotudUSc4DMqZ8DNtUX0vo-VycxFMWb2BzFTqVes3klM6VrZAbM76_-YlNy_TA3XyYNbnuzQZzdPwcng1-JBv1jH8Bj2z3Ep6uoQu-gtkpO7Dz-d3N72nox2FbFqHM2cKxk8X814VdMr_B-sh5SJBjGGbHvF_IxpTUfndzO6Y2EmyMS-pu9xpmx0enB5N06KKQGh_6yrTVTeMUikpIlEXrnNCuaK2pDHJUFkvpSiNkI3Ru8gwzK1SFyrWO-5FCYfEGtrpFZ98Bk4V2ufIeJcqW7lexbDmWWVnaMtde9RNIVytYmwFinDpdzOseHJnXtOJ1XPEEPkf6nz24xl8pd1YMqQclu6y5KCstCOE9gY9x2KsH3XlgZxfXRKOEj9EypRN42_Mv_qrwzmSuVJlAtcHZSEDQ25sj3Y_zAMFNsuYj1zwBHoTgH9OvR4eTaXx6_z8vfYAnnNJpwunPDmxdLa_trveHrpq9IPJ7sD06nH79fg8vsAVV |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BOUAPFc8SKGAkJE5RE8eP-NgtVAt0qx52JW7RJLHVStss2rYHbv0JSPzD_pJ6nKzpqkJIHCNPEsvj8Tw88w3AB6xVU0hVpy7zO9hrjCb1alimORqFpnToGqp3nhyp8Ux8_S5X2YRUC9PjQ8SAG0lGOK9JwCkgvfsHNRTbEyol5wEaU96HB0JxTbLJxXEMs3gNm6vQqtSLJqd8rmwF3Zjx3fVPrKumO_bm3bTJ2-Zs0EcHj2FrMCTZXs_5J3DPdk9h8xa84DOYTdm-nc-vr35NQkMO27KIZc4Wjh0v5j_P7JL5E9a7zkOGHMMwO-YNQzairPbrq98j6iPBRrik9nbPYXbwebo_Toc2CmnjfV-ZtqaunUJRComyaJ0TxhWtbcoGOSqLWjrdCFkLkzd5hpkVqkTlWsf9SKGweAEb3aKzL4HJwrhceZMSZUsXrKhbjjrT2urceNlPIF2tYNUMGOPU6mJe9ejIvKIVr-KKJ_Ax0v_o0TX-SrmzYkg1SNl5xYUujSCI9wTex2EvH3TpgZ1dXBKNEt5Jy5RJYLvnX_xV4a3JXCmdQLnG2UhA2NvrI93pScDgpmJu77rmCfCwCf4x_Wrv03gSn179z0vv4OF4OjmsDr8cfXsNjzjl1oRQ0A5sXCwv7RtvHF3Ub8P2vwESKgct |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkRAcEG8CBYyExClq4vgRH7stq-Wx1R66Um_RxA-10pKtlvbArT8BiX_YX4LtZM2uKoTEMfIksWY8nhl75huA99gKXXHR5q7wK9hbDJ17M8zzEpVAVTt0OtQ7T4_EZM4-n_CTjSr-Hh8iHbgFzYj7dVDwc-P2_oCGojkNleQ0ImPy23An3vgFbGc2S6cs3sCWInYq9ZpJQzpXsUZuLOje9ie2LdMNd_Nm1uSmNxvN0fghPBj8SLLfC_4R3LLdY7i_gS74BObH5MAuFtdXP6exH4c1JEGZk6Ujs-Xixze7In6D9ZHzkCBHMM6OeL-QjEJS-_XVr1FoI0FGuArd7Z7CfPzx-GCSD10Ucu1DX54b1bZOIKsZR14Z55hylbG61khRWJTcSc14y1SpywILy0SNwhlH_UglsHoGO92ysy-A8Eq5UniPErkJ3EZpKMpCSitL5VU_g3zNwUYPEOOh08Wi6cGRaRM43iSOZ_Ah0Z_34Bp_pdxdC6QZlOx7Q5msFQsI7xm8S8NePcKdB3Z2eRloBPMxWiFUBs97-aVfVd6ZLIWQGdRbkk0EAXp7e6Q7O40Q3KGW20euZQY0LoJ_TL_ZP5xM09PL_3npLdydHY6br5-OvryCezRk1sSDoF3YuVhd2tfeNbpo38TV_xuBQgZf |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=T+Cell%E2%80%90Mediated+Transport+of+Polymer+Nanoparticles+across+the+Blood%E2%80%93Brain+Barrier&rft.jtitle=Advanced+healthcare+materials&rft.au=Ayer%2C+Maxime&rft.au=Schuster%2C+Markus&rft.au=Gruber%2C+Isabelle&rft.au=Blatti%2C+Claudia&rft.date=2021-01-01&rft.issn=2192-2640&rft.eissn=2192-2659&rft.volume=10&rft.issue=2&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fadhm.202001375&rft.externalDBID=10.1002%252Fadhm.202001375&rft.externalDocID=ADHM202001375 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2192-2640&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2192-2640&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2192-2640&client=summon |